Compare FVCB & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FVCB | SLN |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 88 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.0M | 300.9M |
| IPO Year | 2018 | N/A |
| Metric | FVCB | SLN |
|---|---|---|
| Price | $17.80 | $10.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $18.00 | ★ $42.60 |
| AVG Volume (30 Days) | 179.8K | ★ 622.1K |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | ★ 47.56 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $1,781,000.00 | N/A |
| Revenue This Year | $13.83 | N/A |
| Revenue Next Year | $7.45 | N/A |
| P/E Ratio | $51.80 | ★ N/A |
| Revenue Growth | ★ 13.87 | N/A |
| 52 Week Low | $11.83 | $4.19 |
| 52 Week High | $18.32 | $11.06 |
| Indicator | FVCB | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 62.14 | 63.62 |
| Support Level | $15.34 | $5.87 |
| Resistance Level | $17.97 | $11.06 |
| Average True Range (ATR) | 0.50 | 0.82 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 69.35 | 73.46 |
FVCBankcorp Inc is a registered bank holding company. It operates through the sole subsidiary, which is a community-oriented, locally-owned, and managed commercial bank. It offers commercial banking services to small and medium-sized businesses, professionals, non-profit organizations and associations, and investors. It also provides retail banking services to accommodate the individual needs of both corporate customers as well as the communities it serves. The bank provides other facilities such as online banking, mobile banking, remote deposit service, and lending products, among others. Its primary source of revenue is the net interest income.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.